BLEEDnFIRE Therapeutics is a biotech company developing first-in-class RNAi therapies to rebalance hemostasis in severe bleeding disorders. Our lead program, BnF-001, selectively targets a hepatic anticoagulant to provide durable bleed protection without factor replacement, addressing key limitations of current therapies. The approach is particularly provide safe and durable treatment for patients underserved by existing treatments. BLEEDnFIRE holds granted IP in the USA, Canada, Japan, and South Korea. The founding team combines complementary expertise in hematology, RNA therapeutics, translational medicine, and biotech entrepreneurship, positioning the company for efficient clinical translation and global partnering.
19.12.2025
4th Patent
20.11.2025
Incorporation BLEEDnFIRE Therapeutics AG - Bern
14.10.2025
Innosuisse Core coaching - Phase II validated
16.06.2025
siRNA screening finalized/leads candidates selected
30.03.2025
In vitro, in vivo & ex vivo PoC confirmed
No Jobs
No videos and documents
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.